TENX.OQ - Tenax Therapeutics Inc
Guggenheim Securities LLCPrice Target Increase
TENX: Increasing PT to $34 Ahead of Phase 3 LEVEL Readout Coming in 3Q26 – We Recommend Investors Own What Could Be the First Positive Pivotal Trial in PH-HFpEF, a Megablockbuster Pot’l Market
公司
TENX.OQ
日期
2026-03-16
分析师
Mr. Seamus Fernandez
页数
7 页
需要登录
请登录后购买研报或生成音频内容。